Extracted from this filing and checked against the source text.
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Serina Therapeutics, Inc. entered into Reaffirmation and Amendment Agreement with Juvenescence Limited (effective 2023-02-09).
- Action
- entry
- Counterparty
- Juvenescence Limited
- Effective
- 2023-02-09
Exact text from the filing
In connection with the Amended Note, AgeX and Juvenescence entered into a Reaffirmation and Amendment Agreement (the "Reaffirmation Agreement") pursuant to which AgeX reaffirmed its obligations under certain agreements between AgeX and Juvenescence that originally pertained to the Original Note, including but not limited to (i) the Security Agreement, (ii) a Registration Rights Agreement, as amended, and (iii) a Warrant Agreement.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Serina Therapeutics, Inc. entered into Amended and Restated Secured Convertible Promissory Note with Juvenescence Limited valued at additional $2,000,000 (effective 2023-02-09).
- Action
- entry
- Agreement
- notes offering
- Counterparty
- Juvenescence Limited
- Value
- additional $2,000,000
- Effective
- 2023-02-09
Exact text from the filing
On February 9, 2023, AgeX and Juvenescence Limited ("Juvenescence") entered into an Amended and Restated Secured Convertible Promissory Note (the "Amended Note") which amends and restates a February 14, 2022 Secured Convertible Promissory Note (the "Original Note") and provides that AgeX may borrow up to an additional $2,000,000 from Juvenescence until May 9, 2023 subject to Juvenescence’s discretion to approve each loan draw.
View on SEC.gov